Pasar al contenido principal

REMODELACION DEL METABOLISMO DE GLUCOSA Y LIPIDOS EN CELULAS ESTRELLADAS HEPATICAS

PID2021-126096NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

  • González Rellán, María Jesús
  • Parracho, Tamara
  • Heras, Violeta
  • Rodríguez, Amaia
  • Fernández Fondevila, Marcos
  • Novoa Deaño, Eva María
  • Lima, Natalia
  • Varela Rey, Marta María
  • Senra, Ana
  • Chantada Vázquez, María del Pilar
  • Ameneiro, Cristina
  • Bernardo, Ganeko
  • Fernández-Ramos, David
  • Lopitz-Otsoa, Fernando
  • Bilbao, Jon
  • Guallar Artal, Diana
  • Fidalgo, Miguel
  • Bravo López, Susana Belén
  • Diéguez, Carlos
  • Martínez-Chantar, María Luz
  • Millet, Óscar
  • Mato, José M.
  • Schwaninger, Markus
  • Prevot, Vincent
  • Crespo, Javier
  • Frühbeck, Gema
  • Iruzubieta, Paula
  • Nogueiras Pozo, Rubén
Objective O-GlcNAcylation is a post-translational modification that directly couples the processes of nutrient sensing, metabolism, and signal transduction, affecting protein function and localization, since the O-linked N-acetylglucosamine moiety comes directly from the metabolism of glucose, lipids, and amino acids. The addition and removal of O-GlcNAc of target proteins are mediated by two highly conserved enzymes: O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) and O-GlcNAcase (OGA), respectively. Deregulation of O-GlcNAcylation has been reported to be associated with various human diseases such as cancer, diabetes, and cardiovascular diseases. The contribution of deregulated O-GlcNAcylation to the progression and pathogenesis of NAFLD remains intriguing, and a better understanding of its roles in this pathophysiological context is required to uncover novel avenues for therapeutic intervention. By using a translational approach, our aim is to describe the role of OGT and O-GlcNAcylation in the pathogenesis of NAFLD. Methods We used primary mouse hepatocytes, human hepatic cell lines and in vivo mouse models of steatohepatitis to manipulate O-GlcNAc transferase (OGT). We also studied OGT and O-GlcNAcylation in liver samples from different cohorts of people with NAFLD. Results O-GlcNAcylation was upregulated in the liver of people and animal models with steatohepatitis. Downregulation of OGT in NAFLD-hepatocytes improved diet-induced liver injury in both in vivo and in vitro models. Proteomics studies revealed that mitochondrial proteins were hyper-O-GlcNAcylated in the liver of mice with steatohepatitis. Inhibition of OGT is able to restore mitochondrial oxidation and decrease hepatic lipid content in in vitro and in vivo models of NAFLD. Conclusions These results demonstrate that deregulated hyper-O-GlcNAcylation favors NAFLD progression by reducing mitochondrial oxidation and promoting hepatic lipid accumulation
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

  • Gonzalez-Rellan, María J
  • Fernández, Uxía
  • Parracho, Tamara
  • Novoa, Eva
  • Fondevila, Marcos F
  • da Silva Lima, Natalia
  • Ramos, Lucía
  • Rodríguez, Amaia
  • Serrano-Maciá, Marina
  • Pérez-Mejías, Gonzalo
  • Chantada-Vazquez, Pilar
  • Riobello, Cristina
  • Veyrat-Durebex, Christelle
  • Tovar, Sulay
  • Coppari, Roberto
  • Woodhoo, Ashwin
  • Schwaninger, Markus
  • Prevot, Vincent
  • Delgado, Teresa C.
  • Lopez, Miguel
  • Díaz-Quintana, Antonio
  • Dieguez, Carlos
  • Guallar, Diana
  • Frühbeck, Gema
  • Díaz-Moreno, Irene
  • Bravo, Susana B
  • Martinez-Chantar, Maria L
  • Nogueiras, Ruben
Neddylation is a post-translational mechanism that adds a ubiquitin-like protein, namely neural precursor cell expressed developmentally downregulated protein 8 (NEDD8). Here, we show that neddylation in mouse liver is modulated by nutrient availability. Inhibition of neddylation in mouse liver reduces gluconeogenic capacity and the hyperglycemic actions of counter-regulatory hormones. Furthermore, people with type 2 diabetes display elevated hepatic neddylation levels. Mechanistically, fasting or caloric restriction of mice leads to neddylation of phosphoenolpyruvate carboxykinase 1 (PCK1) at three lysine residues-K278, K342, and K387. We find that mutating the three PCK1 lysines that are neddylated reduces their gluconeogenic activity rate. Molecular dynamics simulations show that neddylation of PCK1 could re-position two loops surrounding the catalytic center into an open configuration, rendering the catalytic center more accessible. Our study reveals that neddylation of PCK1 provides a finely tuned mechanism of controlling glucose metabolism by linking whole nutrient availability to metabolic homeostasis., This work was supported by grants from: FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación (M.L.M.-C.: PID2020-117116RB-I00; C.D.: BFU2017-87721; M.L.: RTI2018-101840-B-I00; R.N.: PID2021-126096NB-I00 and RED2018-102379-T); Xunta de Galicia (R.N.: 2021-CP085 and 2020-PG0157); Fundación BBVA (to R.N.); Subprograma Retos Colaboración RTC2019-007125-1 (to M.L.M.-C.); Proyectos Investigación en Salud DTS20/00138 (to M.L.M.-C.); Proyectos Investigación en Salud (M.L.M.-C.: DTS20/00138); Fundación Atresmedia (to M.L. and R.N.); and Fundación La Caixa (to M.L., M.L.M.-C., and R.N.). This research also received funding from the European Community’s H2020 Framework Programme (ERC Synergy Grant-2019-WATCH- 810331, to R.N., V.P., and M.S.). The Centro de Investigación Biomédica en Red (CIBER) de Fisiopatología de la Obesidad y Nutrición (CIBERobn) and the Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) are initiatives of the Instituto de Salud Carlos III (ISCIII) of Spain, which is supported by FEDER funds. We thank MINECO for the Severo Ochoa Excellence Accreditation bioGUNE (SEV-2016-0644) to CIC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modulatory effects of CNNM4 on protein- l -isoaspartyl- O -methyltransferase repair function during alcohol-induced hepatic damage

  • González-Recio, Irene
  • Goikoetxea-Usandizaga, Naroa
  • Rejano-Gordillo, Claudia María
  • Conter, Carolina
  • Rodriguez-Agudo, Rubén
  • Serrano-Maciá, Marina
  • Zapata-Pavas, L. Estefanía
  • Close Peña-Sanfélix, Patricia
  • Azkargorta, Mikel
  • Elortza, Félix
  • Herranz, José Maria
  • Guillamon-Thiery, Álex
  • Guerra-Ruiz, Armando Raúl
  • Jover-Atienza, Ramiro
  • Galicia-García, Unai
  • Martín, César A.
  • Schaeper, Ute
  • Cardoso-Delgado, Teresa
  • Díaz-Moreno, Irene
  • Díaz-Quintana, Antonio
  • Buccella, Daniela
  • Nogueiras, Rubén A.
  • Argemi, Josepmaria
  • Ávila, Matías A.
  • Gratacós-Ginès, Jordi
  • Pose, Elisa
  • Bataller, Ramon A.
  • Crespo-García, Javier V.
  • Martínez-Cruz, Luís Alfonso
  • Martínez-Chantar, María Luz
Chemicals and CAS Registry Numbers alcohol dehydrogenase 9031-72-5 methyltransferase 9033-25-4 alcohol 64-17-5 magnesium 7439-95-4 Ethanol Magnesium, ALD, alcohol-associated liver disease; CNNM4, Cyclin M4; ER, endoplasmic reticulum; PCMT1, L-isoaspartate O-methyltransferase; SAMe, S-adenosylmethionine; WT, wild type Supplemental Digital Content is available, Background and Aims: Alcohol-associated liver disease (ALD) is a leading cause of liver-related mortality worldwide, with limited treatment options beyond abstinence and liver transplantation. Chronic alcohol consumption has been linked to magnesium (Mg2+) deficiency, which can influence liver disease progression. The mechanisms underlying Mg2+ homeostasis dysregulation in ALD remain elusive. This study aimed to investigate the role of the Mg2+ transporter Cyclin M4 (CNNM4) in ALD by analyzing its expression patterns in patients with ALD and preclinical animal models. Approach and Results: In this study, CNNM4 is upregulated in the liver of both patients with ALD and animal models. CNNM4 overexpression triggers Mg2+ homeostasis dysregulation, linked to ALD progression. We propose a novel therapeutic approach for ALD treatment using N-acetylgalactosamine silencing RNA technology to specifically modulate Cnnm4 expression in the liver, improving mitochondrial function and alleviating endoplasmic reticulum stress. Notably, silencing Cnnm4 restores protein isoaspartyl methyltransferase (PCMT1) activity, essential for repairing ethanol-induced protein damage. Enhancing mitochondrial activity through Cnnm4-dependent mechanisms increases S-adenosylmethionine levels, crucial for PCMT1 function, highlighting the interconnected roles of mitochondrial health and protein homeostasis in ALD treatment. Conclusions: These findings shed light on the dysregulation of Mg2+ homeostasis in ALD, providing a promising therapeutic approach targeting CNNM4. N-acetylgalactosamine siCnnm4 therapy boosts the repair processes of ethanol-damaged proteins through the upregulation of PCMT1 activity., The authors acknowledge Begoña Rodríguez Iruretagoyena for the technical support., This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: PID2023-146933OB-100 funded by MCIU /AEI /10.13039/501100011033 / FEDER, UE as part of Plan Estatal de Investigación Científica y Técnica e Innovación (to MLM-C); Grant CEX2021-001136-S funded by MCIN/AEI /10.13039/501100011033 (to MLM-C); Instituto de Salud Carlos III (ISCIII) through the project PMP22/00054 "Exploring the Feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors (Immune4ALL)" and co-founded by the European Union; CIBEREHD\Project funded by CIBEREHD; La Caixa Banking Foundation under the project code CI23-20155 (CaixaImpulse) (to MLM-C); La Caixa Banking Foundation and FCT (HR17-00601) (to MLM-C); Programa Ayudas a proyectos de investigación y desarrollo en salud del Departamento de Salud del Gobierno Vasco (2023333041) (to MLM-C); Diputación Foral de Bizkaia dentro del Programa Transferencia Tecnológica 2022 (6/12/TT/2022/00001), co-founded by FEDER (to MLM-C); Proyecto Elkartek, Subvencionado por el Gobierno Vasco (to MLM-C); PhD fellowship from MINECO (REF BES-2017-080435) (to Irene González-Recio); Spanish Ministerio de Ciencia e Innovación (MICINN), Grants No PID2019-109055RB-I00, BFU2016-77408-R and PID2022-141748OB-I00, to L.A.M.-C; and grants by ERANet E-Rare No EJPRD19-040, and by Instituto Carlos III, No G95229142 (to Luis Alfonso Martínez-Cruz); PI22/01853 from reactive to perspective medicine in NAFLD: Identification a novel signature for progression in early NAFLD, PMP21/00112 Dianas terapéuticas y biomarcadores para la medicina de precision en MAFLD (PreMed-MAFLD), PI18/01304 Immunomediatd Nonalcoholic SteaTohepatItis; prevalence and CharacTerization. INSTInCT study (to Javier Crespo and Paula Iruzubieta). Instituto de Salud Carlos III FIS PI22/00910 (to Elisa Pose). Río Hortega grant (to Jordi Gratacós-Ginès), ISCIII-Acción Estratégica en Salud (AES), 2021 Call; FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación PID2021-126096NB-I00 and RED2018-102379-T; Xunta de Galicia 2021-CP085 and 2020-PG0157 (to Rubén Nogueiras); Ministerio de Ciencia, Innovación PID2021-126663NB-I00, European Regional Development Fund (FEDER), Andalusian Government (BIO-198 and P18-FR-3487, US/JUNTA/FEDER, UE), University of Seville (VI PPIT-US), and the Ramón Areces´ Foundation (to Irene Díaz-Moreno); Ministry of Science and Innovation, grant number PID2022-138572OB-C42 (to Cesar Martín); “Ayuda RYC2020-029316-I financiada por MCIN/AEI/10.13039/501100011033 y por EL FSE invierte en tu future” (to Teresa C. Delgado); Instituto Carlos III PI20/00690 (to Ramiro Jover), cofounded by the European Union., Peer reviewed